GH News and Press, Guardant Health Inc. From 06/02/26

2026-06-02 11:12:34 ET could become a trillion-dollar chipmaker jumps on outlook tests chicken wings Read the full article on Seeking Alpha For further details see: Wall Street Lunch: NVIDIA CEO Huang's $1T Marvell Call Triggers $40B Rally, Crushing Puts

2026-06-02 05:19:15 ET More on the markets The Multi-Trillion AI Tsunami Sweeping The Market XPAY Vs. SPY: Choosing Between Yield And Capital Appreciation My Oh My, What A Month Of May SA analyst says semiconductors and AI are powering a fragile market rally ...

New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying actionable biomarkers missed by genomic testing Presentations rei...

2026-05-28 06:44:54 ET More on Health Care stocks AI Revolutionizing Biopharma: Faster, Better, Cheaper Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Small-cap health...

2026-05-27 16:15:00 ET Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to b iotech ETFs, they give sector participants exposure to many biotech companies via one vehicle. ETFs are a popular choice as they al...

2026-05-27 15:16:00 ET The following segment was excerpted from the Baron Health Care Fund Q1 2026 Shareholder Letter . ... Read the full article on Seeking Alpha For further details see: Baron Health Care Fund Q1 2026 Portfolio Activity

2026-05-27 14:15:04 ET from BTIG issued a price target of $160.00 for GH on 2026-05-27 16:52:20. The adjusted price target was set to $160.00. At the time of the announcement, GH was trading at $127.4072. The overall price target consensus is at $133.64 with high price o...

Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are not up to date with their colorectal cancer screening Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines Guardant Health, Inc. (Nasda...

2026-05-20 09:11:29 ET More on Guardant Health Guardant Health: Reveal And Shield Driving The Next Growth Phase Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transc...

Guardant Health’s new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw Approval strengthens Guardant’s leadership in comprehensive molecular profiling and advances a unified t...